Investor News

VIB spin-off Flamingo Therapeutics merges with Dynacure to create leading RNA therapeutics company in oncology

The combined company will continue under the name Flamingo Therapeutics

VIB spin-off Flamingo Therapeutics and Dynacure announced today that both companies have signed a definitive merger agreement. The combined company will continue under the name Flamingo Therapeutics and will further pursue their positioning as a single leading RNA therapeutics company in oncology. Additionally, current investors Kurma Partners and PMV have made a further investment in the company.

Flamingo Therapeutics is a VIB spin-off company that was originally founded in 2020 based on pioneering work by Jean-Christophe Marine (VIB-KU Leuven Center for Cancer Biology) and Pieter Mestdagh (CRIG) in the field of lncRNAs. Bringing together Flamingo Therapeutics's and Dynacure’s expertise, the combined company will advance Flamingo’s lead programs. 

The first program which Flamingo Therapeutics will continue to advance is Danvatirsen, an antisense oligonucleotide (ASO) that selectively targets STAT3 and has shown clinical activity in Phase II clinical studies. The therapeutic effect of STAT3 suppression results in reduction of tumor cell growth as well as activation of anti-tumor immunity mediated by the tumor micro-environment. Currently, Danvatirsen is planned to continue Phase II clinical development for head and neck squamous cell carcinoma to advance the program through key clinical milestones and data readouts. 

In addition, the combined company will also advance FTX-001, Flamingo’s most advanced LncRNA program which targets MALAT-1, through readiness for Phase I in solid tumors. LncRNA has been dubbed the dark matter of the human genome because not much is known about it. However, it proves to be a large class of innovative therapeutic targets. 

Stephane van Rooijen, CEO of Flamingo Therapeutics: “The merger of Flamingo and Dynacure is a great strategic fit for both companies, leveraging a wealth of RNA therapeutic expertise and cancer drug development, and combining teams to create a stronger organization. With our well-defined clinical strategy and operational plan, we are focused on creating value for all stakeholders, including patients, clinicians and our investors. We plan to continue to execute upon our clinical strategy with the combined company and team in place.”
Lies Vanneste

Lies Vanneste

Investor Relations Manager, VIB

Share

Latest stories

Researchers discover clues for Alzheimer’s disease in hibernation

Researchers discover clues for Alzheimer’s disease in hibernation

Leuven, 12 November 2026 – Researchers at VIB and KU Leuven have discovered that hibernation triggers changes in brain cells that partially resemble those in Alzheimer’s disease. Studying golden hamsters, the team identified changes in gene expression across the hibernation cycle, which resemble those associated with the accumulation of amyloid plaques in Alzheimer’s. The findings, published in Science Advances, suggest that some early cellular changes associated with Alzheimer’s may also occur as part of a natural adaptive response, offering new ways to study the disease for therapy development.

press.vib.be

An inside look at a molecular switch that triggers inflammation

An inside look at a molecular switch that triggers inflammation

Ghent, 9 November 2026 – Researchers at VIB and Ghent University have uncovered how an important driver of inflammation is activated at the molecular level. Their findings, published in Science Immunology, also explain how a medicine used to treat a severe form of psoriasis blocks this inflammatory signal.

press.vib.be

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Leuven, 4 November 2026 – Researchers at VIB and KU Leuven have uncovered how mutations in the ASPM gene disrupt the development of neural stem cells that help the human brain grow. This disruption explains how these mutations cause microcephaly, a condition characterized by an abnormally small brain and head, often accompanied by intellectual disability. The discovery, published in Developmental Cell, also sheds light on how differences in brain development can make humans more susceptible to certain genetic conditions than other mammals.

press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be